Autologous Bedside CD19 CAR T-cell Therapy for B-ALL
Autologous Bedside CD19 CAR T-cell Therapy for B-ALL
Not yet recruiting · NCT07277504 · Registry updated 2025-12-11Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Autologous Bedside CD19 CAR T-cell Therapy for B-ALL | B-cell neoplasm, Burkitt lymphoma, DNA Virus Infections, Epstein-Barr virus infection, Hemic and Lymphatic Diseases, Herpesviridae infectious disease, Infections, Neoplasms by Histologic Type, Tumor Virus Infections, immune system disorder, immunoproliferative disorder, lymphatic system disorder, lymphoma, lymphoproliferative syndrome, neoplasm, viral infectious disease | Not yet recruiting | Early phase 1 | 2025-12-11 | NCT07277504 |
2 results · Page 1 of 1
Organizations
Swipe the table sideways for more columns.
| Organizations | Linked trials |
|---|---|
| Chengdu Ucello Biotechnology Co., Ltd. | 5 |
| The General Hospital of Western Theater Command | 26 |
1 results · Page 1 of 1
Research sites
Swipe the table sideways for more columns.
| Research sites | City | Country | Linked trials |
|---|---|---|---|
| The General Hospital of Western Theater Command | Chengdu | China | 9 |